



**Scholars Research Library**  
Der Pharma Chemica, 2011, 3 (5):341-347  
(<http://derpharmachemica.com/archive.html>)



ISSN 0975-413X  
CODEN (USA): PCHHAX

## Synthesis of all the isomers of aliphatic side chain of Microcoline-B

M .Shiva Rama Krishna\*, B.Srinivasulu

*Department of Chemistry, Rayalaseema University, Kurnool-518002(A P), India*

---

### ABSTRACT

*Synthesis of possible isomers of 2, 4-dimethyloctanoic acid, C<sub>2</sub>-methyl centre was fixed by using resolution method and C<sub>4</sub>-methyl group was introduced by Evans asymmetric alkylation method.*

**Keyword:** 2, 4-dimethyloctanoic acid, L-phenylalaninol, alkylation, D-phenylalaninol.

---

### INTRODUCTION

The search for new immunosuppressive agents from natural sources has led to the discovery of structurally diverse and biologically operative compounds. Cyclosporine and FK-506 are the two examples of the natural products that have shown particular promise in the treatment of organ transplantation rejection through suppression of the immune response. Structure activity relationship (SAR) of these compounds lead to the discovery of novel intracellular targets for immunosuppression and new therapeutics devoid of the toxic side effects associated with our current drugs.

The absolute stereochemistry of the three asymmetric centres in the molecule was not assigned in the original isolation work. Comparison of <sup>13</sup>C and <sup>1</sup>H NMR chemical shifts with those of the corresponding majusculamide D compounds seemed to suggest that C<sub>4</sub>-stereochemistry may also be S in the microcolins.

### MATERIALS AND METHODS

**General:** - Melting points were determined in a sulfuric acid-bath and are uncorrected. IR spectra were recorded in KBr on a Shimadzu 435 spectrometer, <sup>1</sup>H NMR spectra on a Varian Gemini 200 MHz spectrometer with TMS as an internal standard and mass spectra on a Perkin Elmer Hitachi RDO-62 and MS-30 instrument.

**i. General Procedure for the synthesis of (2S)-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-2-methylpent-4-enamide (3a) and (2R)-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-2-methylpent-4-enamide (3b):**

To a stirred solution of racemic mixture, ( $\pm$ ) 2- Methyl-4 pentenoic acid (**1**) (37 g, 325 mmol) in dry benzene (200 ml), thionyl chloride (26 ml, 357 mmol) was added at room temperature. The reaction mixture was stirred for 8 h and concentrated to get crude acid chloride (**2**) (42 g).

The acid chloride **2** (42g, 316 mmol) in dry dioxane (100 ml) was added to a stirred solution of L-phenylalaninol (50g, 332 mmol) and triethylamine (69 ml, 632 mmol) in dry dioxane (330 ml) at 5-10<sup>0</sup>C. After 2 h dioxane was removed under reduced pressure and the reaction mixture was neutralized with 1 N HCl. After usual workup, the mixture of amides **3a** and **3b** was subjected to column chromatography by eluting with 25-40% ethyl acetate in hexane to obtain the faster moving amide **3a** (26 g, 32.5%) followed by slower moving amide **3b** (22.4 g, 28%).

**For Amide-Faster (3a):**

$[\alpha]_D^{20}$ : -13.1<sup>0</sup> (c=1.65 in CHCl<sub>3</sub>); Mp : 99-101 °C; IR (KBr): 3570-3325 cm<sup>-1</sup> (-NH, OH), 1660 cm<sup>-1</sup> (C=O); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200MHz):  $\delta$  7.40-7.14 (m, 5H, aromatic), 5.80-5.60 (m, 2H, -NH and -CH=CH<sub>2</sub>), 5.10-4.95 (m, 2H, -CH=CH<sub>2</sub>), 4.26-4.10 (m, 1H, -CHCH<sub>2</sub>OH), 3.72- 3.50 (m, 2H, -CH<sub>2</sub>OH), 2.95-2.75 (m, 2H, -CH<sub>2</sub>Ph), 2.60 (bs, 1H, -OH, D<sub>2</sub>O exchangeable), 2.40-2.00 (m, 3H, -CHCH<sub>3</sub> and allylic CH<sub>2</sub>), 1.05 (d, J=7.25 Hz, 3H, -CHCH<sub>3</sub>).

**Amide-Slower (3b):**

$[\alpha]_D^{20}$ : -3.05<sup>0</sup> (c=1.38 in CHCl<sub>3</sub>); mp: 104-106 °C.; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz):  $\delta$  7.30-7.10 (m, 5H, aromatic), 5.70-5.45 (m, 2H, -NH and -CH=CH<sub>2</sub>), 5.02-4.86 (m, 2H, -CH=CH<sub>2</sub>), 4.20-4.10 (m, 1H, CHCH<sub>2</sub>OH), 3.70-3.50 (m, 2H, -CH<sub>2</sub>OH), 2.90-2.75 (m, 2H, -CH<sub>2</sub>Ph), 2.32-2.00 (m, 3H, -CHCH<sub>3</sub> and allylic CH<sub>2</sub>) 1.05 (d, J=6.12 Hz, 3H, -CHCH<sub>3</sub>).

**ii. (R)-3-((S)-4-((benzyloxy) methyl) pentanoyl)-4-benzyloxazolidin-2-one (5):**

To a stirred solution of acid **4** (1.6 g, 7.2 mmol) and triethylamine (1.1 ml, 7.9 mmol) in dry THF (30 ml) at -78<sup>0</sup>C was added trimethylacetyl chloride (0.93 ml, 7.5 mmol). The resultant white suspension was stirred for 10 min at -78<sup>0</sup>c and 45 min at 0<sup>0</sup>C, it was re-cooled to -78<sup>0</sup>C and a pre-cooled (-78<sup>0</sup>C) solution of metallated oxazolidinone [prepared by the addition of 4 ml (2M) solution in hexane of n-BuLi to a solution of 1.4 g (7.9 mmol) of oxazolidinone) **43** in dry THF (10 ml) at -78<sup>0</sup>c was added via cannula. The reaction mixture at -78<sup>0</sup>C was stirred for 45min at 0<sup>0</sup>C, and then quenched by the addition of saturated aqueous ammonium chloride solution. Volatiles were removed in vacuo and the residue was extracted with DCM (3x30 ml). the combined organic phase was washed with NaHCO<sub>3</sub> solution followed by water, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The crude product was purified by column chromatography using 2:8 mixture of ethyl acetate-hexane to give compound **5** (1.33 g, 48%) as a thick syrup.

$[\alpha]_D^{20}$ : -24.88<sup>0</sup> (c=1.05 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): 7.40-7.10 (m, 10H, aromatic), 4.65-4.50 (m, 1H, C<sub>4</sub>-1H), 4.45 (s, 2H, OCH<sub>2</sub>Ph), 4.05 (d, J=4.50 Hz, 2H, C<sub>5</sub>-2H), 3.40-3.15 (m, 3H, -CH<sub>2</sub>OBn and -CHPh), 3.05-2.85 (m, 2H, -CH<sub>2</sub>CO-), 2.70-2.55 (dd, J=8.99 and 12.58 Hz, 1H, -CHHPh), 2.00-1.70 (m, 2H, C<sub>3</sub>-1H), 1.65 1.45 (m, 1H, -CHCH<sub>3</sub>), 0.95 (D, J=7.19 Hz, 3H, CH<sub>3</sub>CH-)

**iii. (R)-3-((R)-2-((S)-3-(benzyloxy)-2-methylpropyl)hex-4-enoyl)-4-benzyloxazolidin-2-one (6):**

To a solution of compound **5** (1.24 g, 3.3 mmol) in dry THF (10 ml) at  $-40^{\circ}\text{C}$  lithium hexamethyldisilylazide (1M solution in THF, 3.6 ml, 3.6 mmol) was added and stirred at the same temperature for 45 min, ice cooled solution of crotylbromide (1.67 ml, 16.2 mmol) in dry THF (2 ml) was added to the reaction mixture via cannula and stirred for 2 h at the same temperature. Reaction mixture was quenched by the addition of saturated aqueous ammonium chloride solution and volatiles were removed under vacuum. The residue was dissolved in DCM (50 ml) washed with water, dried with  $\text{Na}_2\text{SO}_4$  and concentrated to get pale yellow oil. This was purified by column chromatography using 15 % EtOAc-Hexane mixture as eluent to obtain compound **6** (0.83 g, 58%) as a colorless oil.

$[\alpha]_{\text{D}}: -27.09^{\circ}$  ( $c=0.62$  in  $\text{CHCl}_3$ );  $^1\text{H NMR}$  ( $\text{CDCl}_3$ , 200 MHz): 7.40-7.10 (m, 10H, aromatic), 5.60-5.30 (m, 2H, Olefinic), 4.60-4.45 (m, 1H,  $\text{C}_4$ -1H), 4.40 (s, 2H,  $-\text{OCH}_2\text{Ph}$ ), 4.10-3.78 (2xm, 3H,  $\text{C}_5$ -2H and  $-\text{CH-CO-}$ ), 3.40-3.16 (m, 3H,  $-\text{CH}_2\text{OBn}$  and  $-\text{CHHP}$ ), 2.65-2.45 (m, 1H,  $-\text{CHHP}$ ), 2.40-1.20 (4xm, 8H,  $\text{CH}_3\text{CH}=\text{CH-CH}_2$ ,  $\text{C}_1'$ -2H and  $-\text{CHCH}_3$ ), 0.90 (d,  $J=7.5$  Hz, 3H,  $\text{CH}_3\text{CH-}$ ).

**iv. (R)-2-((S)-3-(benzyloxy)-2-methylpropyl) hexan-1-ol (7):**

To an ice cooled suspension of lithium borohydride (35 mg, 1.6 mmol) in ether was added compound **6** (0.63 g, 1.5 mmol) and  $\text{H}_2\text{O}$  (0.03ml, 1.6 mmol). Reaction mixture was stirred at the same temperature for 1h and quenched with 1 M aqueous NaOH solution. The mixture was stirred until both layers were clear and diluted with ether. Organic layer was separated, washed with brine dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated. The residue was purified by column chromatography using 20% EtOAc-Hexane mixture as eluent to give alcohol **7** (0.24 g, 60%) as a syrup.

$[\alpha]_{\text{D}}: 5.0^{\circ}$  ( $c=0.72$  in  $\text{CHCl}_3$ );  $^1\text{H NMR}$  ( $\text{CDCl}_3$ , 200 MHz): 7.30-7.10 (m, 5H, aromatic), 5.50-5.20 (m, 2H, Olefinic), 4.40 (s, 2H,  $-\text{OCH}_2\text{Ph}$ ), 3.44 (d,  $J=4.55$  Hz, 2H,  $-\text{CH}_2\text{OH}$ ), 3.20 (d,  $J=6.36$  Hz, 2H,  $-\text{CH}_2\text{OBn}$ ), 2.10-1.00 (4xm, 9H,  $\text{C}_2$ -1H,  $\text{C}_1$ -2H,  $\text{C}_2$ -1H,  $\text{C}_3$ -2H and  $\text{C}_6$ -3H), 0.86 (d,  $J=6.36$  Hz, 3H,  $\text{CH}_3\text{CH-}$ ).

**v. (R)-2-((S)-3-(benzyloxy)-2-methylpropyl)hexyl 4-methylbenzenesulfonate (8):**

Compound **7** (0.15 g, 0.57 mmol) dissolved in dry DCM (2ml) was cooled to  $0^{\circ}\text{C}$ . DMAP (0.091 g, 0.7 mmol), tosylchloride (0.120 g, 0.63 mmol) were added and this mixture was stirred at room temperature for 4h. The reaction mixture was diluted with DCM, washed with water dried ( $\text{Na}_2\text{SO}_4$ ) and volatiles were removed under vacuum. Residue was purified by a silica gel column using 15 % EtOAc-hexane to give compound **8** (0.206 g, 86%) as a syrup.

$[\alpha]_{\text{D}}: -2.20^{\circ}$  ( $c=1$  in  $\text{CHCl}_3$ );  $^1\text{H NMR}$  ( $\text{CDCl}_3$ , 200 MHz): 7.70 (D,  $J=7.23$  Hz, 2H, aromatic), 7.30-7.10 (m, 7H, aromatic), 5.50-5.10 (m, 2H, Olefinic), 4.38 (s, 2H,  $-\text{OCH}_2\text{Ph}$ ), 3.90-3.70 (m, 2H,  $-\text{CH}_2\text{OTs}$ ), 3.12 (d,  $J=5.96$  Hz, 2H,  $-\text{CH}_2\text{OBn}$ ), 2.38 (s, 3H,  $\text{CH}_3$  of Tosyl), 2.02-0.95 (5xm, 9H,  $\text{C}_2'$ -1H,  $\text{C}_1$ -2H,  $\text{C}_2$ -1H,  $\text{C}_3$ -2H and  $\text{C}_6$ -3H), 0.80 (d,  $J=6.80$  Hz, 3H,  $\text{CH}_3\text{CH-}$ ).

**vi. 1-(((2S,4R)-2,4-Dimethyloctyloxy)methyl)benzene (9):**

To an ice cooled suspension of LAH (0.017 g, 0.46 mmol) in dry THF (2 ml) was added compound **8** (0.19 g, 0.46 mmol) in THF (1 ml). The reaction mixture was stirred at  $50^{\circ}\text{C}$  for 3 h. Excess LAH was quenched with saturated aqueous  $\text{Na}_2\text{SO}_4$  solution, filtered and washed with

THF (3x5 ml). The combined filtrates were concentrated under vacuum. Residue was dissolved in DCM, washed with water, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The crude compound was purified by passing through silica gel column using 7% EtOAc-Hexane mixture as eluent to give compound **9** (76 mg, 68%) as a liquid.

[ $\alpha$ ]<sub>D</sub>: -8.480 (X=0.33 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): 7.38-7.16 (m, 5H, aromatic), 5.50-5.25 (m, 2H, Olefinic), 4.45 (s, 2H, -OCH<sub>2</sub>Ph), 3.30-3.15 (m, 2H, -CH<sub>2</sub>OBn), 2.10-1.05 (4xm, 9H, C<sub>2</sub>-H, C<sub>3</sub>-2H, C<sub>4</sub>-H, C<sub>5</sub>-2H and C<sub>8</sub>-3H), 0.95-0.80 (2xd, J=6.32 Hz, 6H, C<sub>2</sub>-CH<sub>3</sub> and C<sub>4</sub>-CH<sub>3</sub>).

**vii. (2S,4R)-2,4-Dimethyloctan-1-ol (10):**

A mixture containing compound **9** (70 mg, 0.28 mmol) and 10% palladium on carbon (10 mg) in EtOAc (2 ml) was stirred under hydrogen atmosphere at room temperature for 4 h. the catalyst was filtered through a pad of celite and washed with ethyl acetate. The filtrate was concentrated to afford compound **10** (40 mg, 89%) as a syrupy liquid.

[ $\alpha$ ]<sub>D</sub>: 10.9<sup>0</sup> (c=0.22 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): 3.50-3.30 (m, 2H, -CH<sub>2</sub>-OH), 2.10-1.00 (bm, 10H, C<sub>2</sub>-H, C<sub>3</sub>-2H, C<sub>4</sub>-H, C<sub>5</sub>-2H, C<sub>6</sub>-2H and C<sub>7</sub>-2H), 0.95-0.75 (m, 9H, C<sub>2</sub>-CH<sub>3</sub>, C<sub>4</sub>-CH<sub>3</sub> and C<sub>8</sub>-3H).

**viii. (2S, 4R)-2, 4- Dimethyloctanoic acid (11):**

Oxidation of compound **10** (35 mg, 0.22 mmol) using Jones reagent was carried out by the procedure described earlier. Crude compound was purified by column chromatography using 1:1 ethyl acetate-hexane to give acid **11** (27 mg, 71%) as a thick syrup.

[ $\alpha$ ]<sub>D</sub>: 6.00 (c=0.25 in MeOH), lit 6.50 (c=0.05 in MeOH); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): 2.30-2.10 (m, 1H, C<sub>2</sub>-H), 2.00-1.10 (bm, 12H, C<sub>2</sub>-CH<sub>3</sub>, C<sub>3</sub>-2H, C<sub>4</sub>-H, C<sub>5</sub>-2H, C<sub>6</sub>-2H and C<sub>7</sub>-2H), 0.90-0.72 (m, 6H, C<sub>4</sub>-CH<sub>3</sub> and C<sub>8</sub>-3H).

**ix. (S)-3-((R)-4-((benzyloxy) methyl) pentanoyl)-4-benzyloxazolidin-2-one (13):**

Compound **13** was prepared by using the same procedure as described for compound **5** in 49% yield.

[ $\alpha$ ]<sub>D</sub>: 24.89<sup>0</sup> (c=0.45 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): 7.40-7.10 (m, 10H, aromatic), 4.65-4.45 (m, 1H, C<sub>4</sub>-1H), 4.45 (s, 2H, OCH<sub>2</sub>Ph), 4.15-3.95 (m, 2H, C<sub>5</sub>-2H), 3.40-3.20 (m, 3H, -CH<sub>2</sub>OBn and -CHHPH), 3.00-2.80 (m, 2H, -CH<sub>2</sub>CO), 2.68-2.50 (dd, J=9.09 and 11.36 Hz, 1H, -CHHPH), 1.90-1.70 (m, 2H, C<sub>3</sub>-2H), 1.65-1.45 (m, 1H, -CHCH<sub>3</sub>), 0.94 (d, J=6.81 Hz, 3H, CH<sub>3</sub>CH-).

**x. (S)-3-((S)-2-((R)-3-(benzyloxy)-2-methylpropyl) hex-4-enoyl)-4-benzyloxazolidin-2-one (14):**

Compound **14** was prepared by using the same procedure as described for compound **6** in 58% yield.

[ $\alpha$ ]<sub>D</sub>: 31.11<sup>0</sup> (c=0.45 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): 7.40-7.10 (m, 10H, aromatic), 5.60-5.40 (m, 2H, Olefinic), 4.60-4.45 (m, 1H, C<sub>4</sub>-1H), 4.42 (s, 2H, OCH<sub>2</sub>Ph), 4.10-3.95 (m, 2H, C<sub>5</sub>-2H), 3.95-3.80 (m, 1H, CHCO-), 3.40-3.20 (m, 3H, -CH<sub>2</sub>OBn and -CHHPH), 2.65-2.50 (m, 1H, -CHHPH), 2.40-1.20 (4xm, 8H, C<sub>2</sub>-1H, C<sub>3</sub>-2H, C<sub>6</sub>-3H and C<sub>1</sub>'-2H), 0.92 (d, J=6.81 Hz, 3H, CH<sub>3</sub>CH-).

***xi. (S)-2-((R)-3-(benzyloxy)-2-methylpropyl) hexan-1-ol (15):***

Compound **15** was prepared by using the same procedure described for compound **7** in 61% yield.

$[\alpha]_D$ : -4.7<sup>0</sup> (c=1.4 in CHCl<sub>3</sub>).; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): 7.40-7.15 (m, 5H, aromatic), 5.55-5.25 (m, 2H, Olefinic), 4.42 (s, 2H, -OCH<sub>2</sub>Ph), 3.50-3.40 (m, 2H, -CH<sub>2</sub>OH), 3.20 (d, J=6.81 Hz, 2H, -CH<sub>2</sub>OBn), 2.20-1.00 (4xm, 9H, C<sub>2</sub>-1H, C<sub>1</sub>'-2H, C<sub>2</sub>-1H, C<sub>3</sub>-2H and C<sub>6</sub>-3H), 0.90 (d, J=6.81 Hz, 3H, CH<sub>3</sub>CH-).

***xii. (S)-2-((R)-3-(benzyloxy)-2-methylpropyl) hexyl 4-methylbenzenesulfonate (16):***

Compound **16** was prepared by using the same procedure described for compound **8** in 88% yield.

$[\alpha]_D$ : 7.92<sup>0</sup> (c=0.48 in CHCl<sub>3</sub>).; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): 7.72 (d, J=8.64 Hz, 2H, aromatic), 7.35-7.18 (m, 7H, aromatic), 5.40-5.05 (m, 2H, Olefinic), 4.40 (s, 2H, -OCH<sub>2</sub>Ph), 3.95-3.75 (m, 2H, CH<sub>2</sub>OTs), 3.18 (d, J=6.36 Hz, 2H, -CH<sub>2</sub>OBn), 2.40 (s, 3H, CH<sub>3</sub> of Tosyl), 2.10-0.90 (5xm, 9H, C<sub>2</sub>-1H, C<sub>2</sub>-2H, C<sub>2</sub>-1H, C<sub>3</sub>-2H and C<sub>6</sub>-3H), 0.85 (d, J=6.82 Hz, 3H, CH<sub>3</sub>CH-).

***xiii. 1-(((2R, 4S)-2,4-dimethyloctyloxy)methyl)benzene (17):***

Compound **17** was prepared by using the same procedure described for compound **9** in 68% yield.

$[\alpha]_D$ : 11.7<sup>0</sup> (c=0.62 in CHCl<sub>3</sub>).; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): 7.32-7.14 (m, 5H, aromatic), 5.55-5.22 (m, 2H, Olefinic), 4.45 (s, 2H, -OCH<sub>2</sub>Ph), 3.30-3.10 (m, 2H, -CH<sub>2</sub>OBn), 2.00-1.05 (3xm, 9H, C<sub>2</sub>-H, C<sub>3</sub>-2H, C<sub>4</sub>-H, C<sub>5</sub>-2H and C<sub>8</sub>-3H), 0.95-0.75 (2xd, J=6.82 Hz, 6H, C<sub>2</sub>-CH<sub>3</sub> and C<sub>4</sub>-CH<sub>3</sub>).

***xiv. (2R, 4S)-2, 4-Dimethyloctan-1-ol (18):***

Compound **18** was prepared by using the same procedure described for compound **10** in 91% yield.

$[\alpha]_D$ : 20.0<sup>0</sup> (c=0.32 in CHCl<sub>3</sub>).; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200MHz): 3.5-3.30 (m, 2H, -CH<sub>2</sub>OH), 1.80-1.60 (m, 1H, C<sub>2</sub>-H), 1.60-1.40 (m, 1H, C<sub>4</sub>-H), 1.40-1.05 (m, 8H, C<sub>3</sub>-2H, C<sub>5</sub>-2H, C<sub>6</sub>-2H and C<sub>7</sub>-2H), 1.00-0.80 (m, 9H, C<sub>2</sub>-CH<sub>3</sub>, C<sub>4</sub>-CH<sub>3</sub> and C<sub>8</sub>-3H).

***xv. (2R, 4S)-2, 4-Dimethyloctanoic acid (19):***

Compound **19** was prepared by using the same procedure described for compound **11** in 71% yield.



$[\alpha]_D$ : -5.95<sup>0</sup> (c=0.31 in MeOH). ; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz): 9.00 (bs, 1H, -CO<sub>2</sub>H), 2.65-2.45 (m, 1H, C<sub>2</sub>-H), 1.80-1.10 (m, 12H, C<sub>2</sub>-CH<sub>3</sub>, C<sub>3</sub>-2H, C<sub>4</sub>-H, C<sub>5</sub>-2H, C<sub>6</sub>-2H, and C<sub>7</sub>-2H), 1.05-0.80 (m, 6H, C<sub>4</sub>-CH<sub>3</sub> and C<sub>8</sub>-3H).

## RESULTS AND DISCUSSION


***Synthesis of (2S)-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-2-methylpent-4-enamide (3a) and (2R)-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-2-methylpent-4-enamide (3b):***

Quantitatively the racemic mixture of (±) 2- Methyl-4 pentenoic acid (**1**) in dry benzene, thionyl chloride was added at room temperature. The reaction mixture was stirred for 8 h and concentrated to get crude acid chloride. The acid chloride **2** in dry dioxane was added to a stirred

solution of L-phenylalaninol and triethylamine in dry dioxane at 5-10 °C to give Synthesis of (2S)-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-2-methylpent-4-enamide (**3a**) and (2R)-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-2-methylpent-4-enamide (**3b**):

**Scheme-1****Scheme-2**

## Scheme-3



## REFERENCES

- [1] J.A. Endicott and V. Ling, *Annu. Rev. Biochem.*, 58, 137-171 (1989).
- [2] M.M. Gottesman and I. Pastan, *Annu. Rev. Biochem.* 62, 385-427 (1993).
- [3] V. Ling, S.A. Carlsen, and Y.P. See, *Adv. Exp. Med. Biol.*, 84, 247-264 (1977).
- [4] S.P.C. Cole, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M.V. Duncun, R.G. Deeley, *Science*, 258, 1650-1654 (1992).
- [5] M.L. Slovak, J.P. Ho, G.Bhardwaj, E.U. Kurz, R.G. Deeley, S.P.C. Cole, *Cancer Res.*, 53, 3221 - 3224(1993).
- [6] a) T. Efferth and M. Volm, *Cancer Lett.*, 70, 197-202 (1990); b) A.L. Harris and D. Hochhauser, *Acta, Oncolo.*, 31, 205-213 (1992); c) M. De La Torre, X.Y.Hao, R. Larsson, P.Nygren, T. Tsuruo, B.Mannervikand J.Bergh, *Anticancer Res.*, 13, 1425-1430 (1993).
- [7] K.Dano, *Biochem. Biophys. Acta.*; 323, 466-483 (1973).
- [8] C.F.Higgins and M.M. Gottesman, *Trends. Biochem. Sci.*; 17, 18-21 (1992).
- [9] S.M.Simon, D. Roy and M.Schindler, *Proc. Natl. Acad. Sci. USA*, 91, 1128-1132 (1994).
- [10] W.T.Beck, *Biochem. Pharmacol.* 36, 2879-2887 (1987).